Shenzhen Kangtai Biological Products Co., Ltd.

Symbol: 300601.SZ




Market price today

  • 64.8138

    P/E Ratio

  • 0.5018

    PEG Ratio

  • 24.02B

    MRK Cap

  • 0.01%

    DIV Yield

Shenzhen Kangtai Biological Products Co., Ltd. (300601-SZ) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Xiang Miao
Full-time employees:2018
Address:Science and Technology Park

Shenzhen Kangtai Biological Products Co., Ltd. researches, develops, produces, and sells various types of human vaccines in China. The company's products include cell-free whitebait b-type haemophilus influenzae combined vaccine, SARS-COV-2 vaccine, recombinant hepatitis B vaccine, 23-valent pneumococcal polysaccharide vaccine, diphtheria tetanus acellular pertussis and haemophilus influenzae type b combined vaccine, haemophilus influenzae type b conjugate vaccine, measles and rubella combined with live attenuated vaccine, 13-valent pneumococcal conjugate vaccine, rabies vaccine, inactivated poliomyelitis vaccine, and HIB conjugate vaccine. It has an agreement between YTB and Yong Tai Berhad in relation to the development and commercialization of Covid-19 inactivated vaccine in Malaysia. Shenzhen Kangtai Biological Products Co., Ltd. was founded in 1992 and is based in Shenzhen, China.

General Outlook

In simple terms, Shenzhen Kangtai Biological Products Co., Ltd. has 1098.505 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.833% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.098%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.118%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.025% return, is a testament to Shenzhen Kangtai Biological Products Co., Ltd.'s adeptness in optimizing resource deployment. Shenzhen Kangtai Biological Products Co., Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.039%. Furthermore, the proficiency of Shenzhen Kangtai Biological Products Co., Ltd. in capital utilization is underscored by a remarkable 0.024% return on capital employed.

Stock Prices

Shenzhen Kangtai Biological Products Co., Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $22.63, while its low point bottomed out at $21.94. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Shenzhen Kangtai Biological Products Co., Ltd.'s stock market.

Liquidity Ratios

Analyzing 300601.SZ liquidity ratios reveals its financial health of the firm. The current ratio of 215.05% gauges short-term asset coverage for liabilities. The quick ratio (149.49%) assesses immediate liquidity, while the cash ratio (40.88%) indicates cash reserves.

Current Ratio215.05%
Quick Ratio149.49%
Cash Ratio40.88%

Profitability Ratios

300601.SZ profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 9.27% underscores its earnings before tax deductions. The effective tax rate stands at -27.41%, revealing its tax efficiency. The net income per EBT, 127.41%, and the EBT per EBIT, 94.94%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 9.77%, we grasp its operational profitability.

Pretax Profit Margin9.27%
Effective Tax Rate-27.41%
Net Income per EBT127.41%
EBT per EBIT94.94%
EBIT per Revenue9.77%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.15, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

Days of Sales Outstanding149
Days of Inventory Outstanding609
Operating Cycle934.24
Days of Payables Outstanding538
Cash Conversion Cycle397
Receivables Turnover1.12
Payables Turnover0.68
Inventory Turnover0.60
Fixed Asset Turnover0.53
Asset Turnover0.21

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 0.33, and free cash flow per share, -0.38, depict cash generation on a per-share basis. The cash per share value, 0.94, showcases liquidity position. A payout ratio of 0.10 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.12, offers insight into cash flow relative to sales.

Operating Cash Flow per Share0.33
Free Cash Flow per Share-0.38
Cash per Share0.94
Payout Ratio0.10
Operating Cash Flow Sales Ratio0.12
Free Cash Flow to Operating Cash Flow Ratio-1.15
Cash Flow Coverage Ratio0.15
Short Term Coverage Ratio2.01
Capital Expenditure Coverage Ratio0.46
Dividend Paid and Capex Coverage Ratio0.44
Dividend Payout Ratio0.02

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 16.42%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.25, we discern the balance between debt and equity financing. The long-term debt to capitalization, 18.92%, and total debt to capitalization, 20.15%, ratios shed light on its capital structure. An interest coverage of 2.67 indicates its ability to manage interest expenses.

Debt Ratio16.42%
Debt Equity Ratio0.25
Long Term Debt to Capitalization18.92%
Total Debt to Capitalization20.15%
Interest Coverage2.67
Cash Flow to Debt Ratio0.15
Company Equity Multiplier1.54

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 2.86, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.12, reflects the portion of profit attributed to each share. The book value per share, 8.12, represents the net asset value distributed per share, while the tangible book value per share, 7.70, excludes intangible assets.

Revenue Per Share2.86
Net Income Per Share-0.12
Book Value Per Share8.12
Tangible Book Value Per Share7.70
Shareholders Equity Per Share8.12
Interest Debt Per Share2.17
Capex Per Share-1.18

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -13.55%, indicates top-line expansion, while the gross profit growth, -0.31%, reveals profitability trends. EBIT growth, -48.56%, and operating income growth, -48.56%, offer insights into operational profitability progression. The net income growth, -110.50%, showcases bottom-line expansion, and the EPS growth, -110.34%, measures the growth in earnings per share.

Revenue Growth-13.55%
Gross Profit Growth-0.31%
EBIT Growth-48.56%
Operating Income Growth-48.56%
Net Income Growth-110.50%
EPS Growth-110.34%
EPS Diluted Growth-110.53%
Weighted Average Shares Growth1.21%
Weighted Average Shares Diluted Growth-0.43%
Dividends per Share Growth178.88%
Operating Cash Flow Growth-66.97%
Free Cash Flow Growth13.90%
10-Year Revenue Growth per Share2030.90%
5-Year Revenue Growth per Share141.27%
3-Year Revenue Growth per Share48.40%
10-Year Operating CF Growth per Share8488.99%
5-Year Operating CF Growth per Share214.45%
3-Year Operating CF Growth per Share-1.44%
10-Year Net Income Growth per Share-1058.37%
5-Year Net Income Growth per Share-154.84%
3-Year Net Income Growth per Share-121.10%
10-Year Shareholders Equity Growth per Share1622.71%
5-Year Shareholders Equity Growth per Share644.42%
3-Year Shareholders Equity Growth per Share197.98%
10-Year Dividend per Share Growth per Share1727.10%
5-Year Dividend per Share Growth per Share1181.24%
3-Year Dividend per Share Growth per Share219.12%
Receivables Growth21.27%
Inventory Growth-31.22%
Asset Growth-2.56%
Book Value per Share Growth-3.15%
Debt Growth-16.39%
R&D Expense Growth126.34%
SGA Expenses Growth77.80%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 36,140,731,490.31, captures the company's total value, considering both debt and equity. Income quality, -4.11, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.02, gauges operational efficiency, while the research and development to revenue, 25.40%, highlights investment in innovation. The ratio of intangibles to total assets, 3.45%, indicates the value of non-physical assets, and capex to operating cash flow, -240.13%, measures reinvestment capability.

Enterprise Value36,140,731,490.31
Income Quality-4.11
Sales General and Administrative to Revenue0.02
Research and Development to Revenue25.40%
Intangibles to Total Assets3.45%
Capex to Operating Cash Flow-240.13%
Capex to Revenue-41.50%
Capex to Depreciation-652.10%
Stock-Based Compensation to Revenue0.32%
Graham Number4.68
Return on Tangible Assets-1.00%
Graham Net Net-1.06
Working Capital2,835,038,130
Tangible Asset Value8,510,175,287
Net Current Asset Value373,836,628
Average Receivables2,202,979,579.5
Average Payables571,164,260.5
Average Inventory892,996,831
Days Sales Outstanding279
Days Payables Outstanding317
Days of Inventory On Hand531

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 2.44, and the price to book ratio, 2.44, reflect the market's valuation relative to the company's book value. The price to sales ratio, 7.65, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -55.23, and price to operating cash flows, 63.83, gauge market valuation against cash flow metrics.

Price Book Value Ratio2.44
Price to Book Ratio2.44
Price to Sales Ratio7.65
Price Cash Flow Ratio63.83
Price Earnings to Growth Ratio0.50
Enterprise Value Multiple23.25
Price Fair Value2.44
Price to Operating Cash Flow Ratio63.83
Price to Free Cash Flows Ratio-55.23
Price to Tangible Book Ratio3.88
Enterprise Value to Sales11.45
Enterprise Value Over EBITDA38.12
EV to Operating Cash Flow66.23
Earnings Yield-0.38%
Free Cash Flow Yield-2.19%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) on the SHZ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 64.814 in 2024.

What is the ticker symbol of Shenzhen Kangtai Biological Products Co., Ltd. stock?

The ticker symbol of Shenzhen Kangtai Biological Products Co., Ltd. stock is 300601.SZ.

What is company IPO date?

IPO date of Shenzhen Kangtai Biological Products Co., Ltd. is 2017-02-08.

What is company current share price?

Current share price is 22.570 CNY.

What is stock market cap today?

The market cap of stock today is 24024991662.000.

What is PEG ratio in 2024?

The current 0.502 is 0.502 in 2024.

What is the number of employees in 2024?

In 2024 the company has 2018.